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Cohort profile
AbstrAct
Purpose To describe a newly created all-Nordic cohort of 
patients with gastro-oesophageal reflux disease (GORD), 
entitled the Nordic Antireflux Surgery Cohort (NordASCo), 
which will be used to compare participants having 
undergone antireflux surgery with those who have not 
regarding risk of cancers, other diseases and mortality.
Participants Included were individuals with a GORD 
diagnosis recorded in any of the nationwide patient 
registries in the Nordic countries (Denmark, Finland, 
Iceland, Norway and Sweden) in 1964–2014 (with various 
start and end years in different countries). Data regarding 
cancer, other diseases and mortality were retrieved from 
the nationwide registries for cancer, patients and causes of 
death, respectively.
Findings to date The NordASCo includes 945 153 
individuals with a diagnosis of GORD. Of these, 48 433 
(5.1%) have undergone primary antireflux surgery. Median 
age at primary antireflux surgery ranged from 47 to 52 
years in the different countries. The coding practices of 
GORD seem to have differed between the Nordic countries.
Future plans The NordASCo will initially be used to 
analyse the risk of developing known or potential GORD-
related cancers, that is, tumours of the oesophagus, 
stomach, larynx, pharynx and lung, and to evaluate the 
mortality in the short-term and long-term perspectives. 
Additionally, the cohort will be used to evaluate the risk of 
non-malignant respiratory conditions that might be caused 
by aspiration of gastric contents.
InTroducTIon
The Nordic Antireflux Surgery Cohort 
(NordASCo) was set up with the purpose of 
examining the consequences of surgery for 
gastro-oesophageal reflux disease (GORD). 
GORD is defined as a ‘condition that develops 
when the reflux of stomach contents causes 
troublesome symptoms and/or compli-
cations’.1 GORD can occur as a result of 
pathological levels of regurgitation of acidic 
stomach contents, often also including alka-
line bile salts and pancreatic enzymes, into 
the oesophagus. The primary symptoms 
of GORD are heartburn and regurgitation 
of stomach contents.2 Other, less common 
symptoms include chest pain, nausea, hoarse-
ness and symptoms associated with bronchial 
aspiration of reflux contents reaching the 
oropharynx, for example, pneumonia, cough 
and other respiratory disorders.2 The preva-
lence of GORD is estimated at 10%–20% in the 
USA and Europe, and less than 5% in Asia.3 
The prevalence has increased during the 
last few decades,4 an increase that correlates 
with the increasing prevalence of obesity, a 
known risk factor for developing GORD.5–7 
Other established risk factors for GORD are 
heredity and tobacco smoking.8–11 GORD 
can lead to complications, including erosive 
oesophagitis, oesophageal strictures, prema-
lignant Barrett’s oesophagus and oesophageal 
adenocarcinoma.2 The primary treatment 
is medical, most often using a proton pump 
inhibitor. An alternative but less often used 
treatment is antireflux surgery, during which 
the fundus of the stomach is wrapped partly 
or completely around the lower oesophagus, 
mechanically hindering GORD.2 Antireflux 
surgery should be considered in patients with 
severe GORD or poor response to medical 
treatment, especially in young, physically fit 
and healthy adults in whom pharmacological 
treatment otherwise would be necessary for a 
long period of time.12
Strengths and limitations of this study
 ► The main strength of the Nordic Antireflux Surgery 
Cohort  is the large number of individuals included, 
constituting the largest cohort to date of patients 
who have undergone antireflux surgery.
 ► The population-based design counteracts selection 
bias and facilitates the generalisability of the 
findings.
 ► The long and complete follow-up in the registries 
enables studies of conditions with an expected 
long latency interval between antireflux surgery and 
disease.
 ► There are variations in clinical practice and coding 
of diagnoses and procedures between the countries, 
including the codes associated with gastro-
oesophageal reflux disease and antireflux surgery.
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The aim of the current paper is to describe the 
NordASCo. The cohort was created to evaluate how anti-
reflux surgery influences the risks for certain cancers and 
other conditions related to GORD, with the potential to 
identify preventive measures. Another aim of the creation 
of the cohort is to evaluate the safety of antireflux surgery 
regarding short-term and long-term mortality and 
morbidity, as well as postoperative complications.
cohorT descrIpTIon
The NordASCo is based on merged data from nation-
wide health data registries from all five Nordic countries, 
that is, Denmark (excluding Greenland and the Faroe 
Islands), Finland, Iceland, Norway and Sweden. The 
principal study design used in the current cohort has 
previously been described in detail elsewhere.13 The study 
design is feasible since all the Nordic countries maintain 
registries of similar structure and contents that include 
the entire population of each country. Additionally, all 
Nordic countries maintain personal identifiers for all 
individuals in the populations, which makes it possible 
to link all individuals’ data between different registries. 
The registries used for constructing the NordASCo were 
the patient registries, cancer registries and the causes of 
death registries. These registries have been described 
in detail elsewhere,14–18 and only a brief description is 
provided here.
The patient registries
The patient registries of the Nordic countries were 
founded in different years, and reached complete 
national coverage in 1978 (Denmark), 1967 (Finland), 
1999 (Iceland), 1997 (Norway) and 1987 (Sweden). The 
patient registries contain codes for diagnoses and surgical 
procedures from all inpatient and specialised outpatient 
care, as well as dates related to hospital stays and outpatient 
appointments. The patient registries also contain diag-
noses of oesophagitis and Barrett’s oesophagus, of value 
for future studies regarding the progression to oesoph-
ageal adenocarcinoma. Validation studies conducted on 
the patient registries have found the completeness and 
accuracy to be high. In Denmark, the positive predictive 
value has been found to range between 15% and 100% 
depending on the diagnosis, although the lowest posi-
tive predictive values were found among gynaecological 
diagnoses, not assessed in the current study.14 In Finland, 
the positive predictive value was 75%–99% for common 
diagnoses.19 In Sweden, the positive predictive value has 
been found to range between 85% and 95% for common 
diagnoses.15
The cancer registries
The cancer registries in the Nordic countries contain 
anatomical and histological coding of all tumours and 
date of diagnosis. Moreover, in many cases, data for how 
the malignancy was found and tumour stage are also 
available. The cancer registry in Denmark was founded in 
1942, with mandatory registration since 1987. The cancer 
registry in Finland was founded in 1953, with mandatory 
registration since 1961. In Norway, Iceland and Sweden, 
the cancer registries were founded in 1951, 1954 and 
1958, respectively, with mandatory reporting since 1953 in 
Norway, and since their initiation in Iceland and Sweden. 
The cancer registries have been validated in several 
studies, and both completeness and accuracy of data have 
been deemed to be high. In Iceland, the completeness 
has been found to be 99.2%, and 96.4% of the tumours 
were morphologically verified.20 The completeness in 
Norway has been found to be 98.8%, with 93.8% morpho-
logically verified.16 In Sweden, approximately 98% of all 
malignancies in the cancer registry are morphologically 
verified, and the completeness of tumour stage has been 
found to be 98.2%.17 21
The causes of death registries
The causes of death registries include date and causes 
of death, including underlying causes of death. These 
registries have been nationwide since their initiation in 
all Nordic countries. The causes of death registries in 
Denmark, Finland, Iceland, Norway and Sweden have 
been electronically available since 1970, 1969, 1952, 1951 
and 1961, respectively.
permIssIons
Ethical permissions were retrieved from the relevant 
ethical committees in Iceland, Norway and Sweden 
(permissions VSN-14–083, 2014/1498–3, 2014/234–31 
and 2015/240–32, respectively). Ethical permissions are 
not required in Denmark and Finland for this type of 
register-based research. Permissions to use the registry 
data for the NordASCo were retrieved from the Data 
Protection Authorities of Denmark and Iceland (permis-
sions 2014-41-3503 and 2014050845, respectively), and 
in Finland from the National Institute for Health and 
Welfare, Statistics Finland and the Population Register 
Centre (permissions THL/1404/5.05.00/2014, TK53-
1555-15 and 2345/410/15). Due to data regulations in 
Denmark, data from Danish registries are not allowed 
to leave Denmark. Therefore, the data from the other 
participating countries were sent to the governmental 
agency Statistics Denmark to allow further data manage-
ment. All data management and analyses are conducted 
on safe servers belonging to Statistics Denmark, accessed 
externally through a safe virtual private network.
parTIcIpanTs
The individuals included in the NordASCo were 
selected based on a recorded diagnosis of GORD in the 
patient registries when these registries were available at 
the time of data retrieval, that is, between 1 July 1979 
and 31 December 2014 in Denmark, 1 January 1968 
and 31 December 2014 in Finland, 1 January 2000 and 
31 December 2013 in Iceland, 1 January 2007 and 31 
December 2013 in Norway, and between 1 January 1964 
and 31 December 2013 in Sweden. All cohort members 
group.bmj.com on October 26, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Maret-Ouda J, et al. BMJ Open 2017;7:e016505. doi:10.1136/bmjopen-2017-016505
Open Access
needed to be above 18 years of age at the time of their 
first GORD diagnosis or primary antireflux surgery. The 
codes used to identify patients with GORD were 530.90, 
539.11, 539.12, 560.40, 551.30, 551.39, 784.30 and 784.39 
in the International Statistical Classification of Diseases 
and Related Health Problems version 7 (ICD-7), 78430, 
55130, 53093 and 53094 in the ICD-8, 7871A, 787B, 
5513A, 553D, 530B-C, 5301A-D and 5301X in the ICD-9, 
and K20, K21, K22.7, K44 and R12 in the ICD-10.
Following the identification of individuals for the 
NordASCo, they were linked using their personal iden-
tity codes to the causes of death registry and the cancer 
registry of each country. Before the delivery of data from 
each country to Statistics Denmark, any identifiable 
data (such as personal identity codes and names) were 
removed, and instead all patients were assigned an arbi-
trary code number to enable future linkages between 
registries. Following delivery, all data were checked for 
correctness and completeness, and to ascertain that no 
personally identifiable variables were left. Thereafter, the 
data from the different registries within each country 
were merged, and subsequently the data from all coun-
tries were merged into one final database, the NordASCo.
The cohort members were categorised into an ‘exposed 
group’, that is, those who underwent primary antireflux 
surgery (open or laparoscopic), and an ‘unexposed 
group’, that is, those who did not undergo such surgery 
during the study period. The operation codes defining 
cohort members who underwent antireflux surgery were 
4054, 4056, 4074, 4076, 4080 and 4084 in the ICD-7. 
Following the implementation of the Nordic Medi-
co-Statistical Committee (NOMESCO) surgical codes in 
the year 1997, JBC and JBW were used. Moreover, older 
Finnish and Swedish surgical codes were used to identify 
antireflux surgery before the ICD-7 (6241, 6242, 6249, 
6251 and 6259 in Finland, and 4272 in Sweden).
Variables and data management
The main variables in the NordASCo are shown in figure 1. 
Further, the data management of the patient registries 
is shown in figure 2. Exact date of birth was lacking in 
Sweden and Norway, due to data handling regulations 
only permitting delivery of year and month of birth. Due 
to this, the 15th of each month was set as the date of birth 
in these countries. Data were retrieved from as long as 
possible back in time, limited by the year of initiation 
and nationwide coverage of the patient registries in each 
country. All cohort members were followed up through 
the relevant registries until the date of the outcome of 
interest in each study, death or end of the study period, 
whichever occurred first. The patient registries in the 
various countries were retrieved until varying end dates, 
mainly due to the date of submission of the data order. 
The maximum follow-up was therefore until the end of 
the year 2013 for Iceland, Norway and Sweden, and the 
end of 2014 for Denmark and Finland. The arbitrary 
Figure 1 Variables used from different registries within each Nordic country for participants of the Nordic Antireflux Surgery 
Cohort.
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numbers that were used to replace the personal identity 
codes used for linkage are kept in each of the relevant 
agencies in each country. These arbitrary numbers can 
be used for future follow-up of all cohort members as well 
as adding data from additional registries for assessing 
other exposures and outcomes of interest. Furthermore, 
the arbitrary numbers could be used if data need to be 
checked regarding completeness and correctness.
sTudIes
The NordASCo will be used to measure the risk of 
developing known or potential GORD-related cancers 
following antireflux surgery. The initial focus will be on 
how the risk of oesophageal adenocarcinoma develops 
over time after surgery, compared with the risk develop-
ment of oesophageal squamous cell carcinoma and gastric 
adenocarcinoma. Other tumours of potential interest are 
cancer of the larynx, pharynx and lung, which might be 
associated with GORD, although fewer studies support 
these associations and any association with lung cancer 
is controversial.22–24 Additionally, the NordASCo will be 
used to evaluate whether antireflux surgery decreases the 
risk of non-malignant conditions that might be caused 
by aspiration of acidic gastric contents, for example, 
asthma, pneumonia and cardiovascular morbidity and 
mortality.25 26 Due to a general decrease in the number of 
antireflux procedures performed, with one explanation 
being the risk of postoperative mortality and complica-
tions following antireflux surgery, further studies are 
needed to assess these risks and to identify individuals 
who would benefit most from such surgery.
Findings to date
In total, 945 153 individuals with a GORD diagnosis 
have been included in the NordASCo. Characteristics 
of the cohort members are presented in table 1. Of all 
Figure 2 Data management of the patient registries in the Nordic Antireflux Surgery Cohort. GORD, gastro-oesophageal reflux 
disease.
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participants, 48 433 (5.1%) underwent a primary anti-
reflux surgery during the study period and 896 720 
(94.9%) did not. The proportion of patients with a regis-
tered GORD diagnosis who underwent antireflux surgery 
varied between countries, and was lower in Denmark, 
Norway and Sweden (2.8%, 0.7% and 4.0%, respectively) 
compared with Finland and Iceland (48.3% and 28.5%), 
which might also reflect substantial differences in clinical 
practice and registration routines. The sex distribution 
was more even among both the operated and non-oper-
ated cohort members. The surgery group was generally 
younger (25.5% ≥60 years at entry) than the non-surgery 
group (50.4% ≥60 years old at entry). The median age 
at primary antireflux surgery ranged from 47 to 52 years 
in the different countries. Most cohort members were 
included during the time periods 1985–1999 (41.0%) 
and 2000–2014 (56.2%) in the antireflux surgery group, 
and during the time period 2000–2014 in the non-oper-
ated group (76.0%).
Figure 3 shows the annual incidence of primary anti-
reflux surgery among adults in the Nordic countries 
per 100 000 inhabitants, including both open and lapa-
roscopic techniques. The rate in Denmark and Norway 
remained fairly stable during the study period. For both 
Finland and Sweden, a plateau was seen during the end 
of the 1990s, followed by a decrease. In Iceland, a similar 
pattern was seen, but with a later peak in 2003. Due to 
the relatively small population in Iceland, large variations 
in rates were seen but with only small differences in the 
absolute number of procedures. The total number of 
primary antireflux surgery conducted per year is shown 
in figure 4. This figure also shows a peak in the number 
of primary antireflux procedures in the Nordic countries 
Table 1 Characteristics of individuals included in the entire 
Nordic Antireflux Surgery Cohort (NordASCo), as well as the 
numbers and percentage within each characteristic category 
undergoing antireflux surgery
Entire NordASCo
Number (% 
distribution)
Antireflux surgery
Number (% within 
category)
Total 945 153 (100.0) 48 433 (5.1)
Country
  Denmark 243 137 (25.7) 6912 (2.8)
  Finland 42 044 (4.4) 20 328 (48.3)
  Iceland 4545 (0.5) 1296 (28.5)
  Norway 192 290 (20.3) 1429 (0.7)
  Sweden 463 137 (49.0) 18 468 (4.0)
Sex
  Male 462 755 (49.0) 27 169 (5.9)
  Female 481 280 (51.0) 21 264 (4.4)
Age at entry (in 
years)
  18–29 64 033 (6.8) 3395 (5.3)
  30–39 94 945 (10.0) 7379 (7.8)
  40–49 141 323 (15.0) 11 717 (8.3)
  50–59 181 894 (19.2) 13 614 (7.5)
  ≥60 462 958 (49.0) 12 328 (2.7)
Calendar period 
(year)
  1979–1984 38 161 (4.0) 1370 (3.6)
  1985–1999 189 017 (20.0) 19 855 (10.5)
  2000–2014 717 975 (76.0) 27 208 (3.8)
Figure 3 Rate of primary antireflux procedures per 100 000 inhabitants in the five Nordic countries of the Nordic Antireflux 
Surgery Cohort, in 1980–2014.
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around the year 2000, followed by a decline and a stabilisa-
tion until the year 2013. The year 2014 includes data only 
from Denmark and Finland. The decrease in the number 
of procedures from 1994 to 1996, with a rebound in 1997, 
is most likely due to a lack of specific codes representing 
laparoscopic antireflux surgery before the implementa-
tion of NOMESCO. Thus, many laparoscopic procedures 
may have been registered using a different surgical code 
that was less specific, and therefore not possible to include 
in the current cohort.
Data regarding open or laparoscopic technique are 
available since 1997 (figure 5). The countries were 
grouped into two groups, one where data from the entire 
period 1997–2013 are available (Denmark, Finland and 
Figure 4 Total numbers of primary antireflux procedures per year in the Nordic Antireflux Surgery Cohort, in 1980–2014.
Figure 5 Number of primary antireflux procedures conducted using open or laparoscopic technique in the Nordic Antireflux 
Surgery Cohort, 1997–2013. Countries where data from the entire period were available are grouped (Denmark, Finland and 
Sweden), as are countries where only part of the study period was available (Iceland and Norway).
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Sweden), and one group where all years were not avail-
able (Iceland and Norway). There was a steady decline in 
the number of primary antireflux procedures using open 
technique. An increase in the number of primary antire-
flux procedures conducted using laparoscopic approach 
was seen until the year 2000, followed by a decline, which 
corresponds to the general decrease in the total number 
of primary antireflux procedures performed.
To date, two studies have been published based on data 
collected for the NordASCo, although these were based 
on the Swedish part of the cohort only. One study assessed 
the short-term mortality following primary laparoscopic 
fundoplication in the working age population (18–65 
years) during the time period 1997–2013, and revealed 
an almost negligible risk of mortality and low risk of reop-
eration.27 The other study examined the risk of mortality 
following secondary antireflux surgery and identified no 
deaths.28
strength and limitations
The main strength of the NordASCo is the large number 
of individuals included. This creates opportunities for 
subgroup analyses, for example, regarding various time 
intervals and disease risk following antireflux surgery. The 
population-based design counteracts selection bias and 
facilitates the generalisability of the findings. The long 
and complete follow-up in the registries enables studies of 
conditions with an expected long latency interval between 
antireflux surgery and disease, for example, cancer to be 
conducted. Furthermore, the Nordic countries have simi-
larities in their publicly financed healthcare systems and 
have comparable demographic and socioeconomic char-
acteristics of the populations. Virtually all diagnoses and 
surgical procedures with defined codes are available for 
the members of the NordASCo.
Among the main weaknesses is the potential variation 
in clinical practice and coding of diagnoses and proce-
dures between countries, including the codes associated 
with GORD and antireflux surgery. This can be seen in 
the varying proportions of codes representing GORD 
and antireflux surgery from each country. For example, 
48.3% of the patients with a GORD diagnosis in Finland 
underwent antireflux surgery, but the GORD group only 
constitutes 4.4% of the entire NordASCo. In Norway, on 
the other hand, a limited 0.7% of patients with GORD 
underwent antireflux surgery, but patients with GORD 
represent 20.3% of the entire NordASCo. This could 
mean that only the most severe cases of GORD requiring 
inpatient healthcare will receive such a diagnostic code 
in Finland. This would, however, lead to an underestima-
tion of the number of individuals in the non-operated 
GORD group, and selection of the more severe cases, 
thus leading to an underestimation of any preventive 
effect of antireflux surgery. However the accuracy of the 
GORD diagnosis when recorded should be good. The 
main reason for discrepancies is probably non-recording 
of GORD diagnosis, which is not a major methodolog-
ical issue in this cohort study. Nevertheless, adjustment 
or stratification for country might be justified in future 
studies based on this cohort. Furthermore, subanalyses 
of patients with severe GORD (Barrett’s oesophagus or 
oesophagitis), where more objective measurements are 
used for diagnosis, would be valuable. Another limita-
tion is the lack of data on potential variables of relevance 
for the conditions studied, for example, medication and 
lifestyle exposures, including body mass index, tobacco 
smoking and dietary factors.
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